All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Monoclonal B-cell lymphocytosis (MBL) is a pre-leukemic form of chronic lymphocytic leukemia (CLL), characterized by a clonal B-cell presence in the absence of clinical symptoms and organ involvement, with < 5000 monoclonal B lymphocytes/µl in peripheral blood. Approximately 1−2% of patients with MBL progress to CLL, annually.